ARM`s 2022 Cell & Gene State of the Industry Briefing - Video

The Alliance for Regenerative Medicine’s annual Cell & Gene State of the Industry Briefing, a top-level gathering for key stakeholders in the field. This webinar includes ARM’s annual yearly update on the sector’s progress, followed by two panel sessions featuring top CEOs and executives highlighting future inflection points for cell and gene therapies in the coming year. Introduction & Industry Update Janet Lambert, CEO, Alliance for Regenerative Medicine Emile Nuwaysir, Ph.D., CEO, Ensoma; Chairman, Alliance for Regenerative Medicine (ARM); Chairman, BlueRock Therapeutics 2022: A Banner Year for Rare Genetic Disease Therapies? Bob Smith, Senior Vice President, Global Gene Therapy Business, Pfizer Inc. (Moderator) Harold Bernstein, M.D., Ph.D., Chief Medical Officer and Senior Vice President, BioMarin Jason Cole, Chief Business Officer, bluebird bio Bobby Gaspar, M.D., Ph.D., CEO, Orchard Therapeutics Suma Krishnan, Founder and Chief Operating Officer, Krystal Biotech Next Generation Therapies to Fight Cancer Robert Ang, CEO, Vor Biopharma (Moderator) Osvaldo Flores, Ph.D., CEO, Century Therapeutics Steven Kelly, President and CEO, Carisma Therapeutics Alison Moore, Ph.D., Chief Technical Officer, Allogene Therapeutics